Shattuck Labs (STTK) to Release Earnings on Thursday

Key Points

• Shattuck Labs will report Q1 2026 results before the market opens on Thursday, May 7, with analysts expecting EPS of ($0.14) and a conference call scheduled for Friday, May 8 at 4:00 PM ET.
• In the prior quarter the company reported EPS of ($0.12) that met estimates but posted a large revenue miss of $1.00 million versus $0.17 million expected, and analysts project a full-year EPS of about -$1 for the current fiscal year.
• Shares opened at $7.09 and were trading down roughly 5.8%, with a market cap near $535.9M; the stock carries an average analyst rating of “Moderate Buy” and a consensus price target of $12.50.

Shattuck Labs (NASDAQ:STTK - Get Free Report) is expected to post its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Shattuck Labs to post earnings of ($0.14) per share for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last announced its earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). The business had revenue of ($1.00) million for the quarter, compared to the consensus estimate of $0.17 million. On average, analysts expect Shattuck Labs to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shattuck Labs Trading Down 5.8%

Shares of STTK stock opened at $7.09 on Thursday. Shattuck Labs has a 12 month low of $0.71 and a 12 month high of $8.33. The stock has a market cap of $535.88 million, a PE ratio of -9.21 and a beta of 1.28. The company's fifty day moving average price is $6.14 and its 200-day moving average price is $4.14.

Hedge Funds Weigh In On Shattuck Labs

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in Shattuck Labs in the 3rd quarter worth about $38,000. AQR Capital Management LLC raised its position in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock worth $41,000 after buying an additional 31,355 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Shattuck Labs in the 2nd quarter worth about $44,000. Squarepoint Ops LLC purchased a new position in Shattuck Labs in the 3rd quarter worth about $46,000. Finally, Bridgeway Capital Management LLC raised its position in Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company's stock worth $73,000 after buying an additional 55,000 shares during the last quarter. Hedge funds and other institutional investors own 58.74% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. TD Cowen restated a "buy" rating on shares of Shattuck Labs in a report on Friday, March 6th. Wedbush upped their price target on shares of Shattuck Labs from $4.00 to $8.00 and gave the stock an "outperform" rating in a research note on Friday, March 6th. Citigroup upped their price target on shares of Shattuck Labs from $4.00 to $7.00 and gave the stock a "neutral" rating in a research note on Friday, March 13th. HC Wainwright upped their price target on shares of Shattuck Labs from $6.00 to $18.00 and gave the stock a "buy" rating in a research note on Monday, April 20th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $12.50.

Shattuck Labs Company Profile

Shattuck Labs, Inc NASDAQ: STTK is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company's lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.